Nephra
Nephra provides continuous, real-time electrolyte monitoring to help manage and personalize care for dialysis patients. The company combines biosensing hardware with machine learning and artificial intelligence to measure electrolyte levels during dialysis and flag clinically relevant changes. Nephra operates in the medical device and biotechnology research category and targets clinical dialysis settings and care teams as primary users. Its platform includes AI-driven analytics and real-time data integrations for clinical workflows. The solution addresses a large, regulated dialysis market where continuous monitoring can improve patient outcomes and clinical decision-making.
Nephra
Nephra provides continuous, real-time electrolyte monitoring to help manage and personalize care for dialysis patients. The company combines biosensing hardware with machine learning and artificial intelligence to measure electrolyte levels during dialysis and flag clinically relevant changes. Nephra operates in the medical device and biotechnology research category and targets clinical dialysis settings and care teams as primary users. Its platform includes AI-driven analytics and real-time data integrations for clinical workflows. The solution addresses a large, regulated dialysis market where continuous monitoring can improve patient outcomes and clinical decision-making.
TL;DR
What they do: Continuous, real-time electrolyte monitoring for dialysis patients using biosensing hardware and ML/AI
HQ: Champaign, Illinois, United States
Founding year: 2021
Early funding: $70,000 seed / pre-seed (May 2021)
Primary users: Clinical dialysis settings and care teams
Company Overview
Problem Domain
Electrolyte monitoring and patient safety in dialysis
Founded
2021
Industry
Biotechnology
Funding Track Record
70000
Investors reported include iVenture Accelerator and VentureWell; other institutional backers listed in some profiles include Gies College of Business (University of Illinois Urbana-Champaign).